The Filing Desk

Agios Pharmaceuticals

AGIO · Nasdaq · Health Care · Financials, fiscal 2016 to 2025

AGIO · Last close · November 13, 2026
$31.59
Value Agios Pharmaceuticals yourself

Agios Pharmaceuticals' revenue rose 48.0% to $54 million in fiscal 2025. Its operating margin was −873.9%, up from −1,166.5% a year earlier. Free cash flow was −$377 million. The diluted share count rose 0.1%.

AGIOS PHARMACEUTICALS, INC. Latest fiscal year ended December 31, 2025 10-K filed February 12, 2026 · 0001439222-26-000025 Updated
Revenue
$54M
48.0%
Operating margin
−873.9%
292.6 pts
Net income
−$413M
$674M a year earlier
Free cash flow
−$377M
 
Return on equity
−30.2%
87.5 pts
Market cap
$1.9B
Nov 13 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

What Agios Pharmaceuticals does

Agios is a drug company focused on rare diseases, starting with blood disorders. Its main medicine, mitapivat, activates an enzyme called pyruvate kinase in red blood cells to treat hemolytic anemias, in which red blood cells break down too fast.

The drug is sold under the brand name PYRUKYND in the United States for anemia in adults with pyruvate kinase deficiency, and in the European Union and Great Britain for that condition. In the United States it is also approved, under the name AQVESME, for anemia in adults with thalassemia, an inherited blood disorder, and it has approval for thalassemia in Saudi Arabia. Agios earns revenue from selling these medicines.

The company is also testing mitapivat in sickle cell disease and in children with pyruvate kinase deficiency, and says it plans to seek US approval for sickle cell disease after meeting with the FDA. It describes a growing pipeline of other rare disease medicines.

Its biggest risks, as it describes them

  • Its medicines may not sell well enough if it does not successfully commercialize them.
  • Doctors and patients may not accept them, or it may not keep up the sales and marketing it needs.
  • Clinical trials may be slow to enroll patients, and early results may not predict later ones.
  • Trials held outside the United States may not be accepted by the FDA.
  • It may spend limited resources on the wrong drug candidate or condition.
From Agios Pharmaceuticals's annual report on Form 10-K, filed February 12, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

From fiscal 2021 to 2024, earnings per share fell 24.0% a year and net income 25.1% a year, while the share count fell by 4%. Agios Pharmaceuticals then lost money in fiscal 2025.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments1,2861,1008061,5001,200
Debt incl. finance leases—————
Net debt (negative means net cash)—————
Net debt to EBITDA—————
Debt to equity—————
Interest coverage—————
Current ratio17.8x13.3x12.3x11.9x11.5x
Quick ratio17.8x13.2x12.0x11.6x11.1x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Agios Pharmaceuticals' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

Over the 12 months between November 14, 2025 and November 13, 2026, no insider bought Agios Pharmaceuticals shares on the open market, and 7 insiders sold $4.3 million, $4.1 million of it under trading plans set up in advance.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
Aug 4, 2026Sarah GheuensChief Medical OfficerSold plan30,000$30.48$914,400Form 4
Jul 1, 2026Sarah GheuensChief Medical OfficerSold plan4,007$37.56$150,503Form 4
Apr 2, 2026Brian GoffChief Executive Officer, DirectorSold plan19,068$34.71$661,850Form 4
Apr 2, 2026James William BurnsChief Legal OfficerSold plan3,280$34.71$113,849Form 4
Apr 2, 2026Tsveta MilanovaChief Commercial OfficerSold plan3,262$34.71$113,224Form 4
Apr 2, 2026Cecilia JonesChief Financial OfficerSold plan3,141$34.71$109,024Form 4
Apr 2, 2026Krishnan ViswanadhanChief Corp Dev & StrategySold plan2,959$34.71$102,707Form 4
Apr 2, 2026Sarah GheuensChief Medical OfficerSold plan2,940$34.71$102,047Form 4
Mar 5, 2026Krishnan ViswanadhanChief Corp Dev & StrategySold plan2,959$27.80$82,260Form 4
Mar 3, 2026Theodore James Washburn Jr.Principal Accounting OfficerSold5,272$28.88$152,255Form 4
Mar 2, 2026Brian GoffChief Executive Officer, DirectorSold plan18,055$28.96$522,873Form 4
Mar 2, 2026James William BurnsChief Legal OfficerSold plan5,218$28.96$151,113Form 4
The latest 12 of 19 trades. Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score———
Rule of 40−1,019.1%−1,036.7%−650.3%
Altman Z''6.4514.7112.52
Accruals ratio−5.2%81.8%−2.7%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailPassFail
Cash from operations is positiveFailFailFail
Return on assets roseFailPassFail
Cash from operations exceeds net incomePassFailPass
Debt fell relative to assets———
Current ratio roseFailFailFail
Share count didn't riseFailFailFail
Gross margin rosePassFailFail
Revenue rose relative to assetsPassPassFail
F-score———
Companies that report no gross profit are scored on the other eight.

Compare

Put Agios Pharmaceuticals side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
Agios PharmaceuticalsFY2548.0%−873.9%−698.3%———
Nektar TherapeuticsFY25−43.9%−253.7%−377.8%——2Compare
Ocular TherapeutixFY25−18.5%−519.8%−417.5%——4Compare
Tango TherapeuticsFY2548.3%−178.4%−224.3%———Compare
Nuvation BioFY25699.0%−338.7%−288.4%———Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

10 years of figures

Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue7043941180014273654
Revenue growth18.2%−38.5%119.5%24.9%−100.0%——88.4%36.1%48.0%
Gross profit7043931170012243248
Research and development220293341214221257280296301340
Operating income−201−321−362−316−336−378−389−392−426−472
Net income−198−315−346−412−3271,605−232−352674−413
Diluted EPS (US$)−5.07−6.75−6.03−6.86−4.7426.55−4.23−6.3311.64−7.12
Diluted shares (millions)39475760696055565858
Cash flow
Cash from operations39−285−304−371−291−407−310−296−390−373
Capital expenditure1057121465124
Free cash flow29−290−311−383−305−413−314−297−392−377
Dividends paid0000000000
Share buybacks000008020000
Acquisitions0000000000
Stock-based compensation42487358625449454353
Balance sheet at fiscal year end
Cash and short-term investments5745688057186701,2861,1008061,5001,200
Debt incl. finance leases——————————
Total assets6196148588918531,4381,2399371,6631,297
Total liabilities260239171250454146138126122104
Shareholders' equity3593766886404001,2921,1018111,5411,193
Margins and ratios
Gross margin100.0%100.0%98.5%98.9%——88.0%89.3%88.6%88.3%
Operating margin−287.6%−745.8%−384.0%−268.2%——−2,732.1%−1,459.5%−1,166.5%−873.9%
Net margin−284.0%−731.6%−366.6%−349.0%——−1,627.8%−1,312.6%1,845.9%−764.0%
Free cash flow margin41.0%−673.9%−329.9%−324.5%——−2,207.6%−1,107.5%−1,072.7%−698.3%
Rule of 40 (growth + FCF margin)59.2%−712.4%−210.5%−299.6%———−1,019.1%−1,036.7%−650.3%
Return on capital——————————
Return on equity−56.4%−85.7%−65.1%−62.0%−63.0%189.7%−19.4%−36.8%57.3%−30.2%
Return on assets−38.2%−51.0%−47.0%−47.0%−37.5%140.1%−17.3%−32.4%51.8%−27.9%
Net debt to EBITDA——————————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Agios Pharmaceuticals' Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Agios Pharmaceuticals.